Search

everythinglearnresearchcommunity

for

Search:↓

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hair follicle improvement and suggest PRP as an alternative.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.

Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

The user stopped using oral minoxidil due to shedding and is continuing with oral finasteride and hair vitamins. They are advised that shedding is temporary and to maintain finasteride use, with examples of others successfully managing hair loss with similar treatments.

A 23-year-old male has been using 0.25mg finasteride daily for 4.5 months to address early-stage male pattern baldness, with positive results and no significant side effects. He plans to continue with this dosage and may consider increasing it or adding minoxidil if necessary.

A 26-year-old male started treatment with 1 mg finasteride and 2.5 mg oral minoxidil on September 25. By November, he noticed significant hair regrowth with no major side effects, except increased hair growth in other areas.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The user is concerned about the effectiveness of a prescribed topical finasteride spray, Alocare, when applied to the scalp. They are unsure if hair might block the solution and reduce its effectiveness.

The conversation suggests that the hair thinning could be due to stress and vitamin deficiency rather than male pattern baldness. It recommends correcting the vitamin deficiency first and considering Minoxidil for hair growth if needed.

The user restored their hairline using a daily pill with 1mg Finasteride, 2.5mg Minoxidil, and 10mg Biotin, but switched to 0.5mg Dutasteride, 2.5mg Minoxidil, and 10mg Biotin due to side effects. They hope the switch will alleviate issues with sex drive and ejaculation.

A user reported a significant increase in testosterone and estradiol levels after taking Finasteride for 5 months, with estradiol levels rising over 2000%. They plan to consult their doctor, suspecting a lab error, as they feel fine with no side effects.

The user has been using finasteride for years and recently started using minoxidil foam, noticing some increased hair density and vellus hairs after one month. They report no scalp issues or side effects and also use a ketoconazole shampoo weekly.

Kevin's YouTube channel was terminated due to a trademark claim, causing frustration among users who found his hair loss content helpful. Many users expressed support for Kevin, mentioning treatments like finasteride and dutasteride, and hoped for his channel's reinstatement.

The conversation is about a user's progress with hair regrowth using topical foam minoxidil (5%) and finasteride (0.25%) from Keeps, with no reported side effects. The user is 32 years old and has not used microneedling.